Thymosin Alpha-1 10mg

What is Thymosin Alpha-1?

Thymosin Alpha-1 (Tα1), also known by its pharmaceutical name thymalfasin, is a naturally occurring peptide composed of 28 amino acids originally isolated from thymic tissue. First characterized by Allan Goldstein in 1977, Tα1 was identified as the principal bioactive component of thymosin fraction 5 (TF5)—a partially purified extract from the bovine thymus gland (Garaci et al., 2007). The peptide has a molecular weight of approximately 3,108 Daltons and features an acetylated N-terminus, a modification that contributes to its biological stability.

Classified as an immunomodulatory peptide, thymosin alpha 1 is derived endogenously from the precursor protein prothymosin alpha (ProTα). Under physiological conditions, Tα1 is produced primarily in the thymus gland, where it plays a crucial role in T-cell development, immune regulation, and the body's natural immune processes. Serum levels decline with age and in immunocompromised states (Dominari et al., 2020). Tα1 is one of the most extensively studied immune-modulating peptides available for research.

Mechanism of Action of Thymosin Alpha-1

Thymosin Alpha-1 exerts its immunomodulatory effects through a pleiotropic mechanism of action that targets multiple arms of both the innate and adaptive immune system. Research has established that Tα1 acts primarily through Toll-like receptors (TLR2 and TLR9) on myeloid and plasmacytoid dendritic cells, triggering downstream signaling cascades that orchestrate a broad spectrum of immune responses (King & Tuthill, 2016).

T-Cell Development and Maturation

At the cellular level, Tα1 promotes the maturation and differentiation of T-cell precursors within the thymus gland, facilitating the development of both CD4+ helper and CD8+ cytotoxic T cells. Studies indicate that Tα1 enhances the expression of T-cell surface markers including CD3, CD4, and CD8, promoting their functional maturation from immature thymocytes into fully competent effector cells. This mechanism is particularly significant in individuals with compromised immune systems where thymic output is diminished (Mao, 2023). Enhanced T cell function represents one of the key components of Tα1's overall immunomodulatory profile.

Dendritic Cell Modulation

Beyond T-cell modulation, thymosin alpha 1 peptide significantly impacts dendritic cell (DC) function. Research demonstrates that Tα1 promotes DC differentiation from bone marrow precursors, upregulates MHC class I and II expression, and enhances antigen-presenting capacity (Xu et al., 2004). In both clinical settings and preclinical models, this DC-modulating activity establishes a critical bridge between innate immune detection and adaptive immune activation.

Natural Killer Cell Activation

Tα1 also enhances natural killer cells (NK cell) cytotoxicity, increases macrophage phagocytic activity, and stimulates the production of key cytokines including interleukin-2 (IL-2), interferon-alpha (IFN-α), and interferon gamma (IFN-γ). Natural killer cell activation by Tα1 plays a vital role in early immune response to pathogens and aberrant cells, working alongside other immune cells to maintain comprehensive surveillance throughout the body.

Cytokine Regulation and Immune Balance

Research suggests that Tα1 modulates the balance between pro-inflammatory and anti-inflammatory cytokines, potentially through activation of the indoleamine 2,3-dioxygenase (IDO) pathway in dendritic cells, which promotes immune tolerance while maintaining pathogen defense (Wei et al., 2023). This dual capacity for supporting immune balance while preventing excessive inflammation—enhancing defense while promoting immune modulation—makes Thymosin Alpha-1 a uniquely balanced immunomodulator. This property distinguishes it from purely immunostimulatory agents such as Selank or KPV, and underscores the immune system's ability to respond in a nuanced fashion when properly supported.

Research Applications

Thymosin Alpha-1 has been the subject of extensive research across multiple therapeutic domains. The following sections outline the primary research applications where this peptide appears to demonstrate significant potential based on published studies. Individuals seeking to understand Tα1's versatility will find that it has been investigated in contexts ranging from viral infections and chronic diseases to autoimmune conditions and vaccine development.

Immune System Modulation and Immunodeficiency Research

The most extensively studied application of Thymosin Alpha-1 is in immune function modulation and immune support. Research demonstrates that Tα1 can restore immune cell function in immunocompromised models, including those with age-related thymic involution, chemotherapy-induced immunosuppression, and post-surgical immune depression. Studies indicate that Tα1 increases T-cell counts, enhances lymphocyte proliferative responses, and restores the CD4+/CD8+ T-cell ratio in subjects with compromised immune systems (King & Tuthill, 2016). This body of evidence supports Tα1 as a leading candidate for research into peptides for immune system support and immune reconstitution strategies to support immune function.

Viral Hepatitis Research (HBV and HCV)

Thymosin Alpha-1 has been extensively studied in the context of chronic hepatitis B and hepatitis C viral infections. In a landmark randomized controlled trial, Chan et al. demonstrated that a 26-week course of Tα1 produced a 40.6% complete virological response rate (clearance of HBV DNA and HBeAg) compared to 9.4% in controls, with the effect continuing to accumulate after cessation (Chan et al., 1998). Multiple clinical studies across diverse populations have confirmed these findings, leading to the approval of Tα1 (as Zadaxin) for hepatitis B in numerous countries. Research suggests that Tα1 enhances viral clearance through augmentation of antiviral T-cell responses and increased production of antiviral cytokines (Tao et al., 2023). These results in infectious diseases research highlight Tα1's potential as an effective alternative or adjunct to other treatments for chronic infections.

Cancer Immunotherapy Research

Thymosin Alpha-1 has generated significant interest in cancer immunotherapy research. Studies indicate that Tα1, when combined with chemotherapy, produces synergistic anti-tumor effects by enhancing anti-tumor immune responses. Research demonstrates that Tα1 can reverse M2 polarization of tumor-associated macrophages, upregulate MHC class I expression on tumor cells, and increase NK cell and cytotoxic T lymphocyte activity. In NSCLC research models, Tα1 significantly improved overall survival in combination with standard approaches (Wei et al., 2023), positioning it as a potential adjunctive agent to reduce inflammation-related adverse events in immuno-oncology.

Vaccine Adjuvant Research

Research into thymosin alpha as a vaccine adjuvant has shown promising results, particularly in elderly and immunocompromised populations who typically exhibit poor vaccine responses. In a pilot clinical trial, Carraro et al. demonstrated that Tα1 significantly enhanced the immunogenicity of a pandemic H1N1 influenza vaccine in hemodialysis subjects, with the Tα1-treated groups fully meeting European regulatory criteria for seroconversion and seroprotection (Carraro et al., 2012). Additional studies have confirmed Tα1's ability to enhance vaccine responses in elderly subjects, suggesting its utility as an adjuvant for immunity enhancement in populations with compromised immune function (Tuthill & King, 2012). This work is particularly relevant during seasonal illness periods when immune resilience is tested.

Sepsis and Critical Illness Research

Thymosin Alpha-1 has been investigated in sepsis, where immune dysregulation contributes to high mortality. Clinical studies have evaluated Tα1's ability to restore immune homeostasis in septic subjects exhibiting profound immunosuppression. Research suggests Tα1 may reduce 28-day mortality by restoring T cell function, improving monocyte HLA-DR expression, and rebalancing cytokine profiles (Pei et al., 2018). Tα1 also shows potential in modulating cytokine storms, resulting in reduced inflammation and supporting its role in inflammation research (Matteucci et al., 2020).

Autoimmune Disorders and Immune Regulation Research

Emerging research has examined Thymosin Alpha-1's role in autoimmune disorders and autoimmune conditions. Unlike conventional immunosuppressive agents, Tα1's mechanism of promoting immune balance rather than blanket suppression makes it a subject of interest for researchers investigating the body's natural processes of immune tolerance. Preclinical studies suggest that Tα1 may help modulate overactive immune responses by promoting regulatory T-cell differentiation and restoring balance among immune cells. This approach to immune regulation may offer insights for managing conditions where the immune system inappropriately targets the body's own tissues, potentially alleviating symptoms associated with immune dysregulation without compromising pathogen defense.

Cystic Fibrosis and Chronic Disease Research

Thymosin Alpha-1 has also attracted research interest in the context of cystic fibrosis (CF) and other chronic diseases. In CF, chronic lung inflammation and recurrent infections significantly impact quality of life. Studies have investigated Tα1's potential beneficial extrapulmonary effects, including its capacity to modulate immune immune activity in the context of persistent infections common in CF subjects. Research into Tα1's application for chronic infections and conditions such as metabolic syndrome continues to expand, offering potential avenues to improve resilience and immune health in complex disease states where maintaining overall well being is a primary research objective.

Published Research Studies

Thymosin Alpha-1 has an extensive publication record spanning more than four decades. A comprehensive review of the literature reveals this peptide to be among the most thoroughly documented immunomodulatory compounds. Below are key published studies that have shaped our understanding:

1. Literature Review (2020): Dominari et al. reviewed Tα1's biochemical properties and applications in the World Journal of Virology, covering its utility in immunocompromised states, malignancies, and sepsis.
2. Immune Modulation Review (2016): King & Tuthill detailed Tα1's pleiotropic mechanism through TLR signaling and its effects on immune cells subsets in Vitamins and Hormones.
3. Hepatitis B RCT (1998): Chan et al. demonstrated 40.6% virological response vs. 9.4% in controls after 26 weeks of Tα1 in Hepatology.
4. Vaccine Adjuvant Trial (2012): Carraro et al. showed Tα1 enhanced H1N1 vaccine immunogenicity in hemodialysis subjects in Vaccine.
5. Cancer Immunotherapy (2023): Wei et al. reviewed Tα1's immunoregulatory mechanisms in cancer in Int Immunopharmacol, confirming innate and adaptive immune responses enhancement.
6. Sepsis Research (2018): Pei et al. demonstrated Tα1's potential to restore immune homeostasis in sepsis in Expert Opin Biol Ther.
7. Cytokine Storm (2020): Matteucci et al. showed Tα1 mitigates cytokine storm in blood cells in Int J Mol Sci.

Dosage Protocols in Research

Note: The following describes dosages used in published research studies and is for research reference only. This is not medical advice. All research involving peptides should be conducted under appropriate institutional oversight and with consultation from a licensed healthcare provider where applicable.

Standard Research Dosing

In published research settings, Thymosin Alpha-1 (as thymalfasin/Zadaxin) has been most commonly administered via subcutaneous injection. The standard dosing protocol used across the majority of published studies is 1.6 mg administered subcutaneously twice weekly. This dosage has been utilized in research for chronic hepatitis B, hepatitis C, cancer immunotherapy, and vaccine adjuvant studies (King & Tuthill, 2016).

In hepatitis B research, durations have ranged from 26 weeks to 52 weeks of twice-weekly dosing at 1.6 mg per injection (Chan et al., 1998). In vaccine adjuvant studies, higher doses of 3.2 mg and 6.4 mg have been evaluated, with both demonstrating enhanced immunogenicity (Carraro et al., 2012). In sepsis research, 1.6 mg subcutaneously once or twice daily for 5–7 days has been the most frequently investigated protocol. Potential side effects reported in these studies were minimal and primarily limited to injection site reactions.

Reconstitution and Preparation

For reconstitution of lyophilized Thymosin Alpha-1, researchers typically use bacteriostatic water or sterile saline as the solvent. The reconstituted solution should be gently swirled rather than shaken to preserve peptide integrity. These peptide therapies require careful handling to maintain biological activity. Detailed reconstitution guidance is available in our peptide reconstitution guide. Any research protocol should be designed under provider guidance from a qualified medical professional or healthcare provider familiar with peptide research methodologies. Human use of research peptides outside of approved settings is strictly prohibited.

Storage and Handling

Proper storage of Thymosin Alpha-1 is essential for maintaining peptide stability and biological activity. Understanding correct handling protocols is critical for preserving the integrity of specific peptides like Tα1.

Lyophilized Storage

In its lyophilized (freeze-dried) form, Tα1 should be stored at -20°C for long-term storage or at 2–8°C (refrigerator temperature) for shorter-term use. The lyophilized powder is highly stable and can retain its potency for extended periods when stored under these conditions, protected from light and moisture.

Reconstituted Solution Storage

Once reconstituted, Thymosin Alpha-1 solutions should be stored at 2–8°C and used within 2–4 weeks. Avoid repeated freeze-thaw cycles, as these can lead to peptide degradation and loss of biological activity. For in vitro experiments requiring extended use, aliquoting the reconstituted solution into single-use volumes prior to freezing at -20°C is recommended. For comprehensive storage guidance, refer to our guide on storing research peptides.

When handling Tα1, standard laboratory practices apply. Reconstitute under sterile conditions and avoid contact with oxidizing agents. Tα1's acetylated N-terminus provides resistance to aminopeptidase degradation, contributing to a favorable stability profile.

Safety Profile in Research

Thymosin Alpha-1 has demonstrated an exceptionally favorable safety profile across decades of research. A comprehensive review of the safety and efficacy data concluded that Tα1 emerges as a well-tolerated and effective immune modulator, with adverse event rates comparable to placebo in controlled research settings (2024 Safety Review).

Research Safety Data

In the landmark hepatitis B study by Chan et al. (1998), no significant side effects were observed with 26–52 weeks of twice-weekly subcutaneous administration. In the vaccine adjuvant study by Carraro et al. (2012), no adverse events were found to be related to Tα1, and the compound did not affect hematology or blood chemistry values. The most commonly reported potential side effects in the published literature are mild and localized, including injection site reactions such as erythema, tenderness, or mild swelling.

Immune Balance vs. Excessive Activation

Importantly, unlike many immunostimulatory agents, Thymosin Alpha-1 does not appear to trigger excessive immune activity or autoimmune reactions. Its mechanism of promoting immune homeostasis rather than unidirectional stimulation contributes to this favorable safety profile. Research suggests Tα1 may actually help prevent excessive T-cell activation and the associated cytokine storm—a finding with significant implications for its use in hyperinflammatory conditions (Matteucci et al., 2020).

Thymosin Alpha-1 for Immune Health and Long-Term Wellness Research

Beyond acute diseases and infectious diseases, researchers have explored the alpha 1 peptide for its potential role in supporting immune health and overall wellness in aging populations. As a naturally occurring peptide produced by the body's natural processes, Tα1 levels naturally decline with age, correlating with reduced thymic output and diminished immune function. This age-related decline in endogenous Tα1 has made it a focal point in longevity and immune support research.

Studies suggest Tα1 supplementation in research models may restore aspects of youthful immune cell function, enhancing the immune system's ability to respond to novel pathogens and maintain surveillance. Researchers investigating how to improve resilience against age-related immune decline find Tα1 compelling. While not a replacement for a balanced wellness routine or overall well being practices, the peptide appears to address fundamental aspects of immune senescence that other approaches may not target. For researchers focused on long-term immune health, Tα1 represents an essential area of ongoing investigation.

Related Peptides

Thymosin Alpha-1 belongs to a broader family of immunomodulatory and tissue-protective peptides that researchers may consider for comparative or complementary studies.

Thymosin Beta-4 (TB-500)

TB-500 (Thymosin Beta-4) is another member of the thymosin family; however, while Tα1 primarily modulates immune function, TB-500 is better known for its roles in tissue repair, wound healing, and anti-inflammatory activity. Both originate from the thymus gland but activate fundamentally different biological pathways.

Complementary Immune-Modulating Peptides

BPC-157 is a cytoprotective peptide with complementary tissue-healing properties, while Selank offers immunomodulatory effects with additional anxiolytic and nootropic properties through distinct mechanisms. For researchers focused on anti-inflammatory peptides, KPV provides targeted NF-κB pathway modulation and may complement Tα1's broader immune-balancing effects in immune regulation research.

Anti-Aging and Neuroprotective Peptides

Researchers studying anti-aging peptides may find interest in comparing Tα1 with Epithalon, which targets telomerase activity and immune senescence through different pathways. Pinealon offers neuroprotective properties, while GHK-Cu addresses tissue remodeling and cellular repair. For researchers investigating metabolic pathways, IPP-3 RT and IPP-2 TRZ represent peptide-based approaches to metabolic syndrome research, complementing Tα1's focus on immune health.

Frequently Asked Questions

What is Thymosin Alpha-1 used for in research?

Thymosin Alpha-1 is used in research primarily for its immunomodulatory properties. Key research areas include immune system enhancement, chronic hepatitis (HBV/HCV), cancer immunotherapy, vaccine adjuvant applications, sepsis and critical care, cystic fibrosis, and age-related immune decline. It is one of the most extensively studied immune-modulating peptides, with approval in over 35 countries as Zadaxin.

How does Thymosin Alpha-1 differ from Thymosin Beta-4 (TB-500)?

While both are members of the thymosin peptide family originally isolated from thymic tissue, they have distinct functions. Thymosin alpha 1 is primarily an immunomodulator that acts through TLR signaling to enhance T-cell maturation, dendritic cells function, and natural killer cells activity. Thymosin Beta-4 (TB-500) primarily promotes tissue repair, cell migration, and wound healing through actin sequestration. The two peptides target fundamentally different biological pathways.

What is the typical dosage of Thymosin Alpha-1 in published research?

The most commonly used dosage in published research is 1.6 mg administered subcutaneously twice weekly. This protocol has been used across hepatitis B/C investigations, cancer immunotherapy studies, and sepsis research. Some vaccine adjuvant studies have evaluated higher doses of 3.2 mg and 6.4 mg. All dosage information is derived from published literature and is for research reference only.

Is the Thymosin Alpha-1 sold here approved for human use?

No. Thymosin Alpha-1 offered by Iron Peak Peptides is supplied strictly for research purposes only. It is not approved for human use and is not intended to diagnose, treat, cure, or prevent any condition. Researchers should consult with a licensed healthcare provider regarding any regulatory considerations for their specific research protocols.

What is the safety profile of Thymosin Alpha-1?

Thymosin Alpha-1 has demonstrated an excellent safety profile across decades of research. Published studies report adverse event rates comparable to placebo, with the most common side effects being mild injection site reactions. Importantly, Tα1 does not appear to cause excessive immune activation or autoimmune disorders, distinguishing it from many other immunostimulatory compounds.

How should Thymosin Alpha-1 be stored?

Lyophilized thymosin alpha should be stored at -20°C for long-term preservation or at 2–8°C for shorter-term storage. Once reconstituted, solutions should be refrigerated at 2–8°C and used within 2–4 weeks. Avoid repeated freeze-thaw cycles and exposure to light or moisture. See our peptide storage guide for complete details.

Can Thymosin Alpha-1 be combined with other peptides in research?

Yes, Thymosin Alpha-1 has been studied in combination with various agents. Research has evaluated Tα1 alongside interferon-alpha for hepatitis research, with chemotherapy agents for cancer immunotherapy, and with vaccines as an adjuvant. Researchers may consider Tα1's immune-modulating properties complementary to tissue-protective peptides like BPC-157 or anti-inflammatory peptides like KPV, though combination protocols should be based on published research.

How does Thymosin Alpha-1 support immune function in research models?

Thymosin Alpha-1 supports immune function through multiple mechanisms: it enhances T cell function and maturation, activates natural killer cells and dendritic cells, promotes interferon gamma production, and helps maintain immune balance. The alpha 1 peptide's ability to modulate rather than simply stimulate the immune response is central to its research value, as it supports the body's natural immune processes without triggering excessive activation.

What role does Thymosin Alpha-1 play in chronic disease research?

In chronic diseases research, Tα1 has been investigated for its potential to restore and maintain immune cell function in subjects with prolonged immune compromise. Research areas include chronic infections, cystic fibrosis, and conditions involving persistent inflammation. The peptide's mechanism of immune modulation rather than outright stimulation makes it of particular interest where long-term immune regulation is the research objective.

Is Thymosin Alpha-1 considered an effective research compound?

Published research positions Thymosin Alpha-1 as one of the most well-documented immune support peptides available. With over four decades of investigation, regulatory approval in 35+ countries, and an extensive safety record, Tα1 remains an essential research compound for laboratories investigating immune health, immune regulation, and the body's natural processes of immune defense. It is considered an effective alternative to other immunomodulatory approaches in preclinical research settings.

Why Buy Thymosin Alpha-1 from Iron Peak Peptides?

Iron Peak Peptides provides researchers with the highest quality Thymosin Alpha-1 available. Every batch undergoes rigorous third-party testing to verify purity, identity, and potency, with quality assurance documentation (quality documentation) available for each lot. Our Thymosin Alpha-1 consistently tests at ≥99% purity via HPLC analysis and mass spectrometry verification.

We source our Tα1 from cGMP-compliant manufacturing facilities and maintain strict cold-chain storage and shipping protocols to ensure peptide integrity. Our 10mg vial size is optimized for research applications, providing sufficient material for extended study protocols.

Iron Peak Peptides offers fast, discreet shipping across the United States, competitive pricing, and responsive customer support. Whether you are investigating immune modulation, viral defense mechanisms, cancer immunology, or vaccine enhancement, our research-grade Thymosin Alpha-1 provides the quality your studies demand.

References

1. Garaci E, et al. Thymosin alpha1: a historical overview. Ann N Y Acad Sci. 2007;1112:225-234. PubMed
2. King R, Tuthill C. Immune Modulation with Thymosin Alpha 1 Treatment. Vitam Horm. 2016;102:151-178. PubMed
3. Dominari A, et al. Thymosin alpha 1: A comprehensive review of the literature. World J Virol. 2020;9(5):67-78. PubMed
4. Chan HL, et al. Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology. 1998;27(5):1383-1387. PubMed
5. Xu W, et al. The modulation of thymosin alpha 1 in the maturation, differentiation and function of murine bone marrow-derived dendritic cells. Int Immunopharmacol. 2004;4(10-11):1413-1424. PubMed
6. Carraro G, et al. Thymosin-alpha 1 (Zadaxin) enhances the immunogenicity of an adjuvated pandemic H1N1v influenza vaccine in hemodialyzed patients: a pilot study. Vaccine. 2012;30(7):1170-1180. PubMed
7. Wei Y, et al. Thymosin α-1 in cancer therapy: Immunoregulation and potential applications. Int Immunopharmacol. 2023;117:109744. PubMed
8. Mao L. Thymosin alpha 1 – Reimagine its broader applications in the immuno-oncology era. Int Immunopharmacol. 2023;117:109952. PubMed
9. Pei F, et al. Thymosin alpha 1 treatment for patients with sepsis. Expert Opin Biol Ther. 2018;18(sup1):71-76. PubMed
10. Tuthill C, King R. Thymosin α1 continues to show promise as an enhancer for vaccine response. Ann N Y Acad Sci. 2012;1270:21-27. PubMed
11. Tao N, et al. Thymosin α1 and Its Role in Viral Infectious Diseases: The Mechanism and Clinical Application. Molecules. 2023;28(8):3539. PubMed
12. Matteucci C, et al. Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells from Coronavirus Disease 2019 Patients. Int J Mol Sci. 2020;22(1):369. PubMed
13. Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1. Expert Opin Biol Ther. 2024. PubMed